Can Lipid Nanoparticles (LNPs) Replace Electroporation For T-Cell Engineering?

By Xiuying Li, Ph.D., Senior Scientist, Technology Development

Electroporation has long served as the standard non-viral method for delivering nucleic acids into T cells, yet its reliance on physical membrane disruption often triggers cellular stress, compromises viability, and limits scalability. Transitioning to lipid nanoparticles (LNPs) provides a gentle, chemically mediated delivery strategy that shields cargo while preserving T cell health and physiological function. Formulating LNPs specifically tailored for hard-to-transfect immune cells unlocks consistent, high-efficiency gene transfer without subjecting delicate cell populations to harsh electrical pulses.

This gentler delivery mechanism supports higher post-transfection survival rates, streamlines downstream expanding protocols, and simplifies the manufacturing pipeline for engineered cell therapies. By shifting from physical disruption to optimized lipid formulations, therapy developers can improve product consistency, lower operational complexity, and build more reliable commercial production workflows.